On May 13, 2025, Barclays analyst Gena Wang made notable adjustments to the financial outlook of Cellectis (CLLS, Financial), an innovative biopharmaceutical company. The analyst maintained an "Overweight" rating for the stock, indicating continued confidence in Cellectis' market prospects.
Despite the maintained rating, Barclays has revised the price target for Cellectis (CLLS, Financial) from $5.00 to $4.00 USD. This adjustment reflects a 20% decrease from the prior target. Investors may need to consider this revised target, which suggests a more conservative outlook on the stock's potential performance in the near term.
The news comes as Cellectis (CLLS, Financial) continues to operate within the competitive NASDAQ environment, focusing on gene-editing technologies. The updated price target and maintained rating could impact market perceptions and investor strategies moving forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Cellectis SA (CLLS, Financial) is $6.29 with a high estimate of $10.00 and a low estimate of $3.00. The average target implies an upside of 344.31% from the current price of $1.41. More detailed estimate data can be found on the Cellectis SA (CLLS) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cellectis SA's (CLLS, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cellectis SA (CLLS, Financial) in one year is $2.79, suggesting a upside of 97.21% from the current price of $1.4147. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cellectis SA (CLLS) Summary page.
